Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
201 is needed for a higher share price and lower dilution in the future plus the extra money and milestones will attract investors. Otherwise you will be raising less money due to the market cap most likely at a lower price which would be risky moving forward.
The damage is done so now if it is close to completed then no question that is what should be done. It can reverse to the 15/20p mark with 201 and come lab contracts rather than a 2p or less placing in the future.
Based on
1) Share price of EUDA
2) Still ongoing. IF it was a failure it would have been announced already. Mergers that complete often take months.
3) Continued confidence of BOD in 201.
4) Both EUDA and TRX need the merger to go ahead so no real reason for it to not go ahead.
Forget Black Cat. The foundations are very strong. FACT.
If you are looking at 1/2 year investment this can go to 50/100p and i'll explain how.
IF 201 is signed it gives them more cash runway with significant milestones. Then inside the next 12 months get CLX out licensed with at least £10 million upfront payment. If 401 completes it gives a better longer term outlook.
The market cap would be about 30/40 million due to the milestones attached from the deals. Then one of these quality projects gets a huge deal in the next two years maybe 30/40 million upfront with a milestone of a few hundred million. The market moves from bear to bull and suddenly the share price is close to £1.
From 3p hold for 1/2 years and see where this goes. The EUDA merger looks on for sure so this is a game changer as the new projects will take over.
EUDA is doing very well. If 201 comes good shortly which is likely then what an investment this would be.
All driven by quality projects. Also looking forward to the CLX update. 3p is a joke SP at the moment longer term we should see massive value.
Agree time to move on from BOD changes.
Pointless addressing Pork's concern as each time you do he comes up with something different. He is not invested.
Focus for BOD should now be getting positive news out and improving the SP rather than wasting time arguing with shareholders.
401 and 201 have already been given away and the deals should be completed soon.
Total BOD members will likely be the same apart from the observer. The suggested by Suzy were not confirmed so it is possible that one of those two will become the CEO or someone else might step down.
They would know more than you do of what has gone on behind the scenes. Best let it be or sell out.
My guess is Cox is needed to finalise the 201 deal and help with the lab as it would be very difficult for a new person if we lose all the work that is in progress and if he goes and Suzy goes then it is total chaos.
We have a shareholder on the board that was backed by a group and a new CEO. You cannot have it all.
How has it increased? Deluded.
Only the CEO gets paid the most and the rest don't get much at all. I would imagine they will get share options moving forward with a lower salary so would need to deliver first. We don't have a second CEO claiming a salary at the moment so talking nonsense as usual.
Official information below and not Porky's nonsense. He lost it all on 4D so nothing will change with him ever.
Cash runway now appears sufficient to carry it well into 2025
Full year 2023E Group net losses along with the cost of establishing/facilitating Inaphaea Biolabs (including the
acquisition of Imagen Therapeutics), resulted in an average estimated cash burn of a little over £200,000/month for
the period. If one now prudently assumes further, albeit somewhat reduced, Group net losses for 2024E, during
which time it utilises the newly raised net funding to accelerate exploitation and integration of its acquired BioBank
materials in tandem with commercial development/brand establishment within Inaphaea while also advancing
its preclinical product pipeline in the absence of further cash acquisition(s), the Group now appears to have runway
sufficient to carry it into Q2 2025.
Between now and then, of course, various upside scenarios suggest this period could become significantly extended.
This could be derived through securing higher volumes of fee-paying service customers for Inaphaea, potential
signing of licensing agreements with external parties willing to pay upfront charges and fund ongoing
development of the Group’s preclinical and/or clinical assets which, in turn, could also attract continuing
milestones instalments. Any such outcome could be both transformative for ValiRx’s balance sheet while also
proving its business model.
Expenses will go up over the years. Natural and for a biotech it is very low.
Revenue will come in through the lab. No question about that and still every chance 201 completes very soon.
Therefore Q2 2025 is likely to be significantly extended.
Agree the company would have been busted without Suzy and Kevin but they made a mess of it with 201 and therefore the share price. Hopefully they can seal the deal with 201 shortly. That will really move the share price big now.
Kevin has stayed to see it through and I suspect Suzy will step down on a high.
She had no choice because otherwise shareholders wanted Kevin gone and then gone after Suzy as well. A combination of experience of shareholders and experience board members is positive.
They have cash until Q2 2025 and with revenue coming in that should be extended. I think 201 will complete so a good cash runway.
You need experience so no choice but to keep him. We have a shareholder on the board and changes as requested.
It is a combination of both experience and shareholder interests which should work. It would have been better had it been Adam before he got turned down.